The company remains on track to submit a U.S. Biologics License Application for tanruprubart in Guillain-Barré syndrome in the fourth quarter. Annexon expanded the ARCHER II trial of vonaprument in geographic atrophy to include an independent 24-month endpoint, while maintaining its planned fourth-quarter assessment of the existing 15-month endpoint. ARCHER II Adds 24-Month EndpointIn GA, Annexon enrolled 659 patients in ARCHER II, exceeding its original target by 30 patients. Annexon expects the full ARCHER II study, including the 24-month analyses, to be completed in the third quarter of 2027. The article "Annexon Q2 Earnings Call Highlights" was originally published by MarketBeat.